What is the share price of Sai Parenteral's Ltd (SAIPARENT) today?
The share price of SAIPARENT as on 24th July 2026 is ₹535.60. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Sai Parenteral's Ltd (SAIPARENT) share?
The past returns of Sai Parenteral's Ltd (SAIPARENT) share are- Past 1 week: -5.80%
- Past 1 month: -11.32%
- Past 3 months: 10.49%
- Past 6 months: 32.02%
- Past 1 year: 32.02%
- Past 3 years: N/A%
- Past 5 years: 32.02%
What are the peers or stocks similar to Sai Parenteral's Ltd (SAIPARENT)?
The peers or stocks similar to Sai Parenteral's Ltd (SAIPARENT) include:What is the market cap of Sai Parenteral's Ltd (SAIPARENT) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sai Parenteral's Ltd (SAIPARENT) is ₹2366.24 Cr as of 24th July 2026.What is the 52 week high and low of Sai Parenteral's Ltd (SAIPARENT) share?
The 52-week high of Sai Parenteral's Ltd (SAIPARENT) is ₹706 and the 52-week low is ₹400.What is the PE and PB ratio of Sai Parenteral's Ltd (SAIPARENT) stock?
The P/E (price-to-earnings) ratio of Sai Parenteral's Ltd (SAIPARENT) is 165.82. The P/B (price-to-book) ratio is 24.70.Which sector does Sai Parenteral's Ltd (SAIPARENT) belong to?
Sai Parenteral's Ltd (SAIPARENT) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Sai Parenteral's Ltd (SAIPARENT) shares?
You can directly buy Sai Parenteral's Ltd (SAIPARENT) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Sai Parenteral's Ltd
SAIPARENT Share Price
NSE₹535.600.76% (-4.10)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
SAIPARENT Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
SAIPARENT Performance & Key Metrics
SAIPARENT Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| — | 24.70 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 44.74 | 5.90 | 0.53% |
SAIPARENT Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
SAIPARENT Company Profile
Sai Parenteral's Limited is an Indian pharmaceutical company engaged in branded generic formulations and CDMO services, offering products across therapeutic areas including cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, vitamins, analgesics, and dermatology in forms such as injectables, tablets, capsules, liquids, and ointments, with a focus on sterile manufacturing for critical care and penicillin therapies.
SUNPHARMA
PE Ratio
40.57
40.57
1Y Return
14.72%
14.72%
Buy Reco %
93.75
93.75
TORNTPHARM
PE Ratio
87.23
87.23
1Y Return
40.96%
40.96%
Buy Reco %
78.57
78.57
CIPLA
PE Ratio
29.38
29.38
1Y Return
5.20%
5.20%
Buy Reco %
66.67
66.67
ZYDUSLIFE
PE Ratio
21.94
21.94
1Y Return
14.15%
14.15%
Buy Reco %
55.17
55.17
LUPIN
PE Ratio
20.32
20.32
1Y Return
22.10%
22.10%
Buy Reco %
55.56
55.56
SAIPARENT Sentiment Analysis
SAIPARENT Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
SAIPARENT Stock Summary · May 2026
The call framed a transitionary growth phase driven by strategic expansion and heavy investment, with consolidated FY26 revenue of INR 381 crore and management targeting INR 750 crore for FY27. Management’s tone was focused and execution‑oriented: they emphasized building an IP‑led, end‑to‑end platform through the recent Noumed acquisition, accelerating dossier commercialization and scaling CDMO exports as the primary growth engine, while simultaneously progressing local manufacturing capacity in Australia and EU‑GMP upgrades in India. They acknowledged a clear tension between near‑term capital intensity and longer‑term margin upside, noting that FY27 will be investment‑heavy with peak leverage and incremental working‑capital demands largely funded from internal accruals plus modest debt. Management expects stronger second‑half performance driven by commercialization and export momentum, reiterated guidance of a near‑17% EBITDA margin target for FY27 alongside the INR 750 crore revenue goal, and said the full financial impact of current investments should become visible in FY28 as assets commission and utilization improves.
SAIPARENT Stock Growth Drivers
SAIPARENT Stock Growth Drivers
8Successful IPO and Strengthened Capital Position
The company completed a successful IPO and listing that brought thousands of new shareholders onto
Transformational Acquisition Converting the Business into a Global IP‑Led Platform
The acquisition of the Australian business converts the company into a global, IP-led platform by
SAIPARENT Stock Challenges
SAIPARENT Stock Challenges
3Large capex with deferred financial impact
A substantial INR 440 crore capital expenditure program is underway but will largely not contribute
Working capital and funding pressure as scale increases
As the business scales management estimates incremental working capital needs at roughly 25–30% of additional
SAIPARENT Forecast
SAIPARENT Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
SAIPARENT
SAIPARENT
Income
Balance Sheet
Cash Flow
Quarterly Normal View
SAIPARENT Income Statement
SAIPARENT Income Statement
Quarterly Normal View
| Quarter | dec 2025 | mar 2026 | ||
|---|---|---|---|---|
| Total Revenue | 99.28 | 200.81 | ||
Operating & Other expenses | 99.71 | 171.84 | ||
EBITDA | -0.43 | 28.97 | ||
| Depreciation/Amortization | 5.79 | 8.18 | ||
| PBIT | -6.22 | 20.79 | ||
| Interest & Other Items | 5.41 | 8.40 | ||
| PBT | -11.63 | 12.39 | ||
| Taxes & Other Items | -4.96 | -0.76 | ||
| Net Income | -6.67 | 13.15 | ||
| EPS | -2.22 | 4.02 |
SAIPARENT Company Updates
FY 2026FY 2026
Investor Presentation
May 26PDF
SAIPARENT Stock Peers
SAIPARENT Past Performance & Peer Comparison
SAIPARENT Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Sai Parenteral's Ltd | 165.82 | 24.70 | — |
| Sun Pharmaceutical Industries Ltd | 40.57 | 5.55 | 0.82% |
| Torrent Pharmaceuticals Ltd | 87.23 | 10.73 | 0.68% |
| Cipla Ltd | 29.38 | 3.30 | 0.92% |
SAIPARENT Stock Price Comparison
Compare SAIPARENT with any stock or ETFCompare SAIPARENT with any stock or ETF
SAIPARENT
SAIPARENT Holdings
SAIPARENT Shareholdings
SAIPARENT Promoter Holdings Trend
SAIPARENT Promoter Holdings Trend
SAIPARENT Institutional Holdings Trend
SAIPARENT Institutional Holdings Trend
Increased Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has increased by 2.47%
Decreased Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has decreased by 1.69%
SAIPARENT Shareholding Pattern
SAIPARENT Shareholding Pattern
SAIPARENT Shareholding History
SAIPARENT Shareholding History
Foreign Institutions
Mutual Funds Invested in SAIPARENT
Mutual Funds Invested in SAIPARENT
No mutual funds holding trends are available
Top 1 Mutual Funds holding Sai Parenteral's Ltd
| Funds (Top 1) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.0000% | Percentage of the fund’s portfolio invested in the stock 0.92% | Change in the portfolio weight of the stock over the last 3 months -2.19% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 0/54 (0) |
Compare 3-month MF holding change on Screener
smallcases containing SAIPARENT stock
smallcases containing SAIPARENT stock
Looks like this stock is not in any smallcase yet.
SAIPARENT Events
SAIPARENT Events
SAIPARENT Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SAIPARENT has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
SAIPARENT Dividend Trend
No Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
SAIPARENT has not given any dividends in last 5 years
SAIPARENT Dividends
SAIPARENT Dividends
Hmm, looks like data is unavailable here. Please come back after some timeSAIPARENT Stock News & Opinions
SAIPARENT Stock News & Opinions
Articles & Videos
Corporate
Corporate
Sai Parenterals arm signs OTC medicines supply agreement with Australian pharmacy networkSai Parenterals announced that the company's subsidiary Noumed Pharmaceuticals had entered OTC medicines supply agreement with Australia's leading pharmacy network with contract valued at Australian Dollars (AUD) 202 millions (equivalent to Rs 1300 crore; 1 AUD = INR 64.5). The agreement is valid for a period of 7.5 years with a further option of 3 years extension upon mutual consent.
3 weeks agoCapital Market - Live
Corporate
Corporate
Sai Parenterals wins export order worth Rs 104.50 crSai Parenterals has received a purchase order valued at USD 11 million at an exchange rate of Rs 95 (Rs 104.50 crore) from PILL CORP, Bulacan, Philippines. The contract is for supply of anti TB products for the Philippines market on exclusivity basis for a period of 10 years.
1 month agoCapital Market - Live
Corporate
Corporate
Sai Parenterals to convene board meetingSai Parenteral's will hold a meeting of the Board of Directors of the Company on 23 May 2026.
2 months agoCapital Market - Live
Corporate
Corporate
Sai Parenterals to convene board meetingSai Parenterals will hold a meeting of the Board of Directors of the Company on 20 April 2026.
3 months agoCapital Market - Live
Corporate
Corporate
Sai Parenteral's to convene board meetingSai Parenteral's will hold a meeting of the Board of Directors of the Company on 20 April 2026.
3 months agoCapital Market - Live
Corporate
Corporate
Sai Parenterals IPO lists today in B groupThe equity shares of Sai Parenterals (Scrip Code: 544742) are listed effective 02 April 2026 and admitted to dealings on the exchange in the list of ''B'' group securities. At 09:09 IST, the pre-open indicative price of the stock was at a premium of 1.79% to the IPO price of Rs 392.
3 months agoCapital Market - Live
Pledged promoter holdings is insignificant